PMA Review Times Increased After User Fee Initiation, Study Affirms
This article was originally published in The Gray Sheet
Executive Summary
Researchers sought to investigate the impact on market access of several health-care “modernization” laws enacted in the past 15 years, finding that legislative efforts have not improved FDA or CMS review efficiency for devices.
You may also be interested in...
Device Industry Expects Quicker Path To Market In Exchange For Doubling Of User Fees
The tentative agreement of $595 million in user fees over five years is more than companies had wanted to spend. But industry negotiators insist it is a good deal, tied to performance goals and process improvements they say will ensure greater speed and predictability in reaching the U.S. market.
Calling All Innovators: FDA And CMS Seek Candidates For Parallel Review Pilot
FDA and CMS are seeking device companies with innovative technologies to participate in the first test of "parallel," or simultaneous, pre-market approval and Medicare coverage reviews.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”